Vumedi
Video and peer-learning platform for physicians, offering clinician-produced content and AI search tools.
Website: https://www.vumedi.com/
Cover Block
Public sources
| Field | Value |
|---|---|
| Name | Vumedi |
| Tagline | Video and peer-learning platform for physicians, offering clinician-produced content and AI search tools. |
| Headquarters | Oakland, US |
| Founded | 2008 |
| Stage | Series B |
| Business Model | B2B2C |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | $100M+ |
| Total Disclosed | ~$104,000,000 [Oak HC/FT, November 2026] |
Links
Public sources
- Website: https://www.vumedi.com/
Executive Summary
PUBLIC Vumedi runs a physician-focused video and peer-learning platform, and it merits investor attention now because Oak HC/FT disclosed a $104 million Series B in November 2026 alongside evidence that the company is extending its education library into AI-assisted clinical search and discovery [Oak HC/FT, November 2026] [Business Wire, November 2026]. Founded in 2008 in Oakland by Roman Giverts, the company has had time to build a long-tail content asset in specialist medicine, with Vumedi describing itself as a platform used by more than 500,000 healthcare professionals, while its own homepage separately references over 450,000 clinicians, a gap that suggests scale is directionally clear even if the exact current user count should be treated cautiously [Vumedi, retrieved 2026] [Doximity, retrieved 2026]. The product centers on clinician-produced educational media, including more than 100,000 physician-led videos and nearly 5,000 podcast episodes across more than 21 specialties, with AI tools that the company says help clinicians ask questions, surface relevant expert perspectives, and compare how specialists approach the same problem [Oak HC/FT, November 2026] [Business Wire, November 2026].
What stands out is less the media format than the supply side: Vumedi appears to have accumulated a specialty-specific content graph over many years, including material associated with institutions such as Cleveland Clinic and Mayo Clinic on the platform, which may give the AI layer more practical relevance than a generic medical search interface [Vumedi, retrieved 2026] [Signalbase, retrieved 2026]. On team, the public record is clearest on Giverts as founder and CEO, with LinkedIn and company materials aligning there, while Chief Education Officer Desirae Hazen appears to be a key operating executive shaping specialty expansion, though much of that role history remains company-described rather than independently reported [LinkedIn, retrieved 2026] [Vumedi, retrieved 2026] [ZoomInfo, retrieved 2026]. The business model is best described as B2B2C from the available evidence: clinicians are the end users, and Vumedi's public-facing materials emphasize physician education and life sciences partnership access, but public sources in this set do not establish pricing, customer concentration, or contract structure with enough precision to go further [Vumedi, retrieved 2026].
The near-term watch items are adoption depth for the AI tools, where the company reported more than 150,000 NPI-verified clinicians and over 1 million interactions in the first year, and whether fresh capital translates into durable product and distribution gains rather than only broader reach [Business Wire, November 2026]. Investors should also watch for cleaner third-party corroboration on user scale, engagement quality, and commercial traction, because several of the strongest operating claims remain company or investor sourced even when they are plausible and internally consistent [Oak HC/FT, November 2026] [Vumedi, retrieved 2026].
Company-stated, unverified -- This section relies on a mix of investor, company, and secondary profile sources, and several material traction claims remain company-only or only partially corroborated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series B |
| Business Model | B2B2C |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | $100M+ total disclosed, approximately $104,000,000 |
How the Company Got Here
PUBLIC Vumedi has been in market long enough that the recent financing is better read as an acceleration point than a company creation event. The company describes itself as a video education platform for clinicians, and public company materials identify Oakland, California as its base, with Roman Giverts listed as founder and CEO [Vumedi, retrieved 2026]. Crunchbase also lists Vumedi as founded in 2008 and headquartered in Oakland, California [Crunchbase, retrieved 2026].
The public record is thin on early corporate milestones, so the clearest chronology starts with founding and then jumps to the current product footprint. By 2026, Vumedi's website said the platform served more than 500,000 clinicians, while its homepage also presented the business as a peer-learning destination for ongoing medical education [Vumedi, retrieved 2026]. That same year, Oak HC/FT announced a $104 million Series B investment in Vumedi, framing the company around a library of more than 100,000 physician-led videos and nearly 5,000 podcast episodes [Oak HC/FT, November 2026].
This leaves a fairly simple public-company narrative. Vumedi appears to have spent much of its life building clinician audience and content depth before surfacing with a large disclosed growth round in November 2026, a sequence that is consistent with a business that reached scale before taking institutional capital [Crunchbase, retrieved 2026] [Vumedi, retrieved 2026] [Oak HC/FT, November 2026]. Public sources used here do not establish a legal entity name beyond the Vumedi brand.
Independently corroborated -- Confirmed by Crunchbase and the company website, with milestone support from Oak HC/FT.
Product and Technology
MIXED
The product is easiest to understand as a clinician education library with an emerging AI retrieval layer on top. Vumedi describes itself as a video education platform for clinicians and says the service is used for ongoing education across rare diseases, clinical trials, and surgical technique refreshers [Vumedi, retrieved 2026]. Public materials also point to a large specialist content base, with more than 100,000 physician-led videos and nearly 5,000 podcast episodes spanning more than 21 specialties, according to Oak HC/FT and a corroborating secondary profile [Oak HC/FT, November 2026] [BriefGlance.com, retrieved 2026].
The content model appears to rely on clinician-produced and institution-linked programming rather than generic medical reference material. Vumedi’s site shows named content from Cleveland Clinic Orthopaedic Case Studies, Cleveland Clinic Rheumatology Case Studies, and Mayo Clinic Proceedings, while a separate profile says contributors include institutions such as Cleveland Clinic, Mayo Clinic, UCSF, Stanford, and NYU [Vumedi, retrieved 2026] [Signalbase, retrieved 2026]. That does not by itself establish exclusive partnerships or formal deployment contracts, but it does suggest the platform's utility depends on trusted expert-created media rather than a standalone software workflow [Vumedi, retrieved 2026] [Signalbase, retrieved 2026].
Vumedi's more recent technical push is in AI-assisted search and question answering. The company said in November 2026 that its expanded AI tools let clinicians ask clinical questions, surface relevant expert perspectives, and compare how specialists approach the same problem, and that these tools were used by more than 150,000 NPI-verified clinicians in their first year, generating more than 1 million interactions [Business Wire, November 2026]. The available public record supports the product surface and early usage, but not the underlying model architecture, data pipeline, or evaluation framework, so any technical-stack discussion would be speculative and is omitted here [Business Wire, November 2026].
Lightly corroborated -- Product scope is corroborated across Vumedi, Oak HC/FT, Business Wire, and secondary profiles, but several important claims, including contributor breadth and user scale, still rely partly on company-linked or single-source evidence.
Where the Demand Sits
PUBLIC
Medical education infrastructure is becoming more investable because the volume of clinical change is rising faster than a physician can absorb through journals, conferences, and traditional continuing education alone, which is the gap Vumedi is positioning itself to serve [Oak HC/FT, November 2026] [Business Wire, November 2026].
The hard limit in this section is that no named third-party TAM, SAM, or SOM estimate was supplied in the source set for Vumedi’s specific market. That rules out a conventional sizing model. The public record instead supports a narrower observation: Vumedi is operating at the intersection of digital clinician education, professional medical media, and clinical knowledge discovery, with product breadth that spans video, podcasts, and AI-assisted search rather than a single-format learning tool [Vumedi, retrieved 2026] [Oak HC/FT, November 2026] [Business Wire, November 2026].
Demand signals in the available sources are usage-based rather than revenue-based, but they are still directionally useful. Oak HC/FT said physicians spend more than 4.3 million minutes per month learning on the platform, while Vumedi and related profiles describe an audience of more than 450,000 clinicians, including a 500,000-plus figure on the company site [Oak HC/FT, November 2026] [Vumedi, retrieved 2026] [Doximity, retrieved 2026]. Business Wire separately reported that Vumedi’s AI tools reached more than 150,000 NPI-verified clinicians and generated more than 1 million interactions within their first year, which suggests clinician demand is extending from passive content consumption into workflow-like knowledge retrieval [Business Wire, November 2026].
The substitute set matters because Vumedi is not competing only with other video libraries. The more relevant alternatives are legacy CME channels, specialty society education, medical journals, in-person conferences, clinician social networks, podcasts, and point-of-need search behavior that increasingly includes AI interfaces. That framing fits the company’s own positioning around peer-to-peer learning and specialist comparison, and it explains why its content mix now includes more than 100,000 physician-led videos and nearly 5,000 podcast episodes across more than 21 specialties [Oak HC/FT, November 2026] [BriefGlance.com, retrieved 2026].
Macro and regulatory forces cut both ways. On the positive side, medical innovation is producing more therapies, procedures, and trial readouts for physicians to keep up with, which is the backdrop Vumedi and Oak HC/FT both cite for expanded digital learning demand [Business Wire, November 2026] [Oak HC/FT, November 2026]. The constraint is that healthcare knowledge products face a higher trust threshold than general-purpose professional media, particularly when AI tools are involved, so audience scale does not automatically translate into defensible monetization unless clinicians view the content as current, specialty-relevant, and credible enough to influence care decisions, an inference supported by Vumedi’s emphasis on physician-led content and named institutional contributors such as Cleveland Clinic and Mayo Clinic content on the platform [Vumedi, retrieved 2026] [Signalbase, retrieved 2026].
| Cited market-relevant signal | Figure | Relevance |
|---|---|---|
| Clinicians on platform | 500,000+ | Indicates addressable audience already aggregated on-platform [Vumedi, retrieved 2026] |
| Physician-led videos | 100,000+ | Suggests content depth across specialties [Oak HC/FT, November 2026] |
| Podcast episodes | Nearly 5,000 | Expands format coverage beyond video [Oak HC/FT, November 2026] |
| Specialties covered | 21+ | Points to cross-specialty reach rather than a single-vertical product [Oak HC/FT, November 2026] |
| Monthly learning time | 4.3M+ minutes | Indicates recurring engagement, though not monetization [Oak HC/FT, November 2026] |
| AI users in first year | 150,000+ clinicians | Suggests demand for search and retrieval, not only media consumption [Business Wire, November 2026] |
The table does not size the market in dollar terms, but it does show why the category is credible: the scarce asset here is clinician attention assembled around trusted specialty content. If that attention remains durable, the adjacent market opportunity likely extends beyond education into clinical discovery and professional influence, though the public evidence in this section does not yet quantify that expansion.
Lightly corroborated -- This section relies on Oak HC/FT, Business Wire, Vumedi, Doximity, BriefGlance.com, and Signalbase. Core usage signals are corroborated across multiple public sources, but no independent third-party market sizing report was available in the supplied research.
Competitive Landscape
MIXED Vumedi appears to sit in a crowded but still distinct corner of clinician education: it is not described in the available sources as a hospital workflow tool or a broad physician social network, but as a specialist content and search layer built around clinician-produced videos, podcasts, and AI-assisted discovery for doctors [Vumedi, retrieved 2026] [Oak HC/FT, November 2026] [Business Wire, November 2026].
On one side are incumbent medical education channels, including traditional continuing education formats and institution-led publishing, which remain embedded in physician habits but are described in the source material only indirectly as the alternatives Vumedi is trying to improve on through peer-to-peer and on-demand learning [Oak HC/FT, November 2026]. Adjacent substitutes include journal content, society education, and hospital-created case material, some of which also appears inside Vumedi's own content ecosystem through contributors such as Cleveland Clinic, Mayo Clinic, UCSF, Stanford, and NYU, according to Signalbase and Vumedi-hosted content pages [Signalbase, retrieved 2026] [Vumedi, retrieved 2026]. That positioning matters, because it suggests Vumedi is competing less on raw content ownership than on aggregation, format, and discovery.
Its defensible edge today appears to be density of clinician-facing educational content plus usage at scale, though the quality of evidence varies by claim. Oak HC/FT says the platform hosts more than 100,000 physician-led videos, nearly 5,000 podcast episodes across more than 21 specialties, and more than 4.3 million learning minutes per month, while Business Wire says Vumedi's AI tools reached more than 150,000 NPI-verified clinicians and generated more than 1 million interactions within their first year [Oak HC/FT, November 2026] [Business Wire, November 2026]. If those figures hold, the practical moat is not simply the video library, but the feedback loop between specialist content, verified clinician usage, and search behavior. That edge looks durable if physician engagement compounds and contributors continue to upload high-signal material; it looks perishable if AI search becomes commoditized and the underlying content graph can be replicated or licensed elsewhere.
The company is more exposed where it does not appear to control the primary physician workflow. The available public sources do not show Vumedi owning the EHR, prescribing interface, hospital credentialing process, or a broader professional identity network, which means discovery may depend on repeat habit rather than deeply embedded enterprise distribution [Vumedi, retrieved 2026] [CB Insights, retrieved 2026]. There is also an evidence gap around monetization and buyer structure. The research supports strong audience and content claims, but it does not establish pricing, retention, or a named enterprise procurement motion, which leaves open the possibility that adjacent education, publishing, or physician-network platforms could compete effectively if they pair trusted distribution with comparable AI discovery.
Over the next 18 months, the most plausible competitive scenario is a split between platforms that can turn clinician attention into a durable knowledge graph and those that remain feature-level content libraries. In that setup, Vumedi is the likely winner if its AI tools continue converting specialist media into faster, higher-trust clinical discovery for verified physicians, because the current public evidence points to meaningful early usage on top of an already large content base [Business Wire, November 2026] [Oak HC/FT, November 2026]. The likely loser if AI search quality stalls is the broader category of standalone medical video libraries, including Vumedi itself, since the same sources that support its current position also imply that relevance, curation, and comparative answers are becoming as important as the media catalog.
Opportunity
PUBLIC The prize here is not another medical media property, it is the chance to become a default clinical learning and discovery layer for practicing physicians at global scale, in a market where trust, specialist context, and speed of retrieval matter every day at the point of care or just before it.
The headline opportunity rests on a simple observation: Vumedi already appears to have the two ingredients that most clinician-facing education products struggle to assemble at the same time, meaningful audience reach and dense specialty content. The company says more than 500,000 healthcare professionals use the platform, while its homepage separately cites 500K+ clinicians and says more than 1 in 4 U.S. doctors are on the platform [Vumedi, retrieved 2026]. Oak HC/FT says the platform includes more than 100,000 physician-led videos, nearly 5,000 podcast episodes across more than 21 specialties, and more than 4.3 million minutes of monthly learning time [Oak HC/FT, November 2026]. If those engagement and supply-side figures hold, the reachable upside is a category-defining physician knowledge network: not only where doctors watch procedures or case studies, but where they ask clinical questions, compare expert approaches, and discover new evidence through an AI layer trained on a proprietary professional content graph [Business Wire, November 2026] [Oak HC/FT, November 2026].
That outcome is still conditional, but it is no longer purely aspirational because the company has already shown signs of cross-format depth. The content base spans video and podcasts, and the AI feature set has already reached reported usage from more than 150,000 NPI-verified clinicians and generated more than 1 million interactions within its first year [Business Wire, November 2026]. That matters because AI products in medical education usually fail when they lack trusted source material or authenticated professional users; Vumedi appears to have both, at least from the public record [Business Wire, November 2026] [Vumedi, retrieved 2026].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Clinical search layer | Vumedi becomes the physician-facing search and answer interface for specialty education, with AI routing clinicians to peer-led videos, podcasts, and expert comparisons rather than generic web results. | The 2026 AI expansion creates a new habitual workflow beyond passive viewing [Business Wire, November 2026]. | The company reports more than 150,000 NPI-verified clinicians used its AI tools in year one, on top of a library of 100,000+ physician-led videos and nearly 5,000 podcasts [Business Wire, November 2026] [Oak HC/FT, November 2026]. |
| Institutional knowledge partner | Vumedi deepens ties with hospitals, academic centers, and life sciences groups until it is the standard distribution channel for specialist education and clinician engagement. | Existing content relationships with named institutions and a larger balance sheet after the Series B support broader outreach [Vumedi, retrieved 2026] [Oak HC/FT, November 2026]. | Public pages show content from Cleveland Clinic and Mayo Clinic properties, and Signalbase says contributors include Cleveland Clinic, Mayo Clinic, UCSF, Stanford, and NYU [Vumedi, retrieved 2026] [Signalbase, retrieved 2026]. |
| Specialty-by-specialty global expansion | Vumedi keeps adding depth in additional specialties and geographies until each new vertical becomes easier to seed than the last. | The $104 million Series B gives the company more capacity for talent, R&D, product development, and outreach [Oak HC/FT, November 2026] [CFO Tech, November 2026]. | Oak HC/FT describes an existing footprint across more than 21 specialties, which suggests the platform has already solved repeatable content and community formation in multiple clinical domains [Oak HC/FT, November 2026]. |
The compounding mechanism is visible in outline even if the public data are still thin. More clinician attention should attract more expert contributors; more contributor supply improves specialty coverage and answer quality; better coverage makes the AI layer more useful; a more useful AI layer increases query volume and retention; that, in turn, gives Vumedi more evidence on what clinicians search for, watch, and revisit across specialties [Business Wire, November 2026] [Oak HC/FT, November 2026]. In practice, this looks less like a classic social network and more like a trust-and-relevance flywheel built on verified professional identity, specialist content density, and repeated learning behavior.
Some signs suggest that flywheel may already be starting. Oak HC/FT points to more than 4.3 million minutes of monthly learning on the platform, while Business Wire says the AI tools crossed 1 million interactions within their first year [Oak HC/FT, November 2026] [Business Wire, November 2026]. The homepage also indicates broad clinician reach and claims content contributions from a high share of top U.S. hospitals, although that institutional contribution figure is company-reported and should be treated cautiously [Vumedi, retrieved 2026]. If Vumedi can turn that engagement into a durable habit for search, case-based learning, and specialty updates, each new content asset should improve the retrieval experience for the next clinician session.
The size of the win is hard to pin down from public evidence because no external market sizing source or clean public comparable is confirmed in the supplied materials. Even so, a useful framing is strategic rather than purely financial: if Vumedi becomes the trusted interface through which hundreds of thousands of physicians discover procedural knowledge, expert opinion, and emerging clinical evidence, it would occupy a control point in professional medical learning that few independent platforms appear to own today, based on the available sources [Vumedi, retrieved 2026] [Oak HC/FT, November 2026]. In that scenario, not a forecast, the company would likely merit valuation logic closer to scaled workflow or knowledge-infrastructure platforms than to niche digital publishers, but the public record here is not strong enough to support a numeric range without introducing unsupported comparables.
Lightly corroborated -- Section relies on Oak HC/FT, Business Wire, Vumedi, and Signalbase. Core product scale and funding are corroborated, but several usage and contribution claims remain company-reported or single-source.
Sources
Public sources
[Oak HC/FT, November 2026] Vumedi: Connecting Physicians to the Expertise that Advances Care | https://www.oakhcft.com/blog-post/vumedi-connecting-physicians-to-the-expertise-that-advances-care
[Business Wire, November 2026] Vumedi Expands AI-Powered Physician Learning as Medical Innovation Accelerates | https://www.businesswire.com/news/home/20261110245713/en/Vumedi-Expands-AI-Powered-Physician-Learning-as-Medical-Innovation-Accelerates
[Vumedi, retrieved 2026] Vumedi | https://www.vumedi.com/
[Doximity, retrieved 2026] VuMedi | https://www.doximity.com/clinicians/company/vumedi
[LinkedIn, retrieved 2026] Roman Giverts | LinkedIn | https://www.linkedin.com/
[ZoomInfo, retrieved 2026] Desirae Hazen | ZoomInfo | https://www.zoominfo.com/
[Crunchbase, retrieved 2026] Vumedi - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/vumedi
[Signalbase, retrieved 2026] Vumedi Company Profile | https://signalbase.ai/companies/vumedi
[BriefGlance.com, retrieved 2026] Vumedi Company Profile | https://briefglance.com/company/vumedi
[CB Insights, retrieved 2026] VuMedi | https://www.cbinsights.com/company/vumedi
[CFO Tech, November 2026] Vumedi expands AI learning tools after USD $104m funding | https://cfotech.news/story/vumedi-expands-ai-learning-tools-after-usd-104m-funding
Articles about Vumedi
- Vumedi's AI Search Taps 100,000 Physician Videos for Peer-to-Peer Learning — The 15-year-old platform, fresh off a $104 million Series B, is using its deep library of specialist videos to power a new wave of clinical AI search.